Detection  ||| S:0 E:10 ||| NNP
of  ||| S:10 E:13 ||| IN
treatment-resistant  ||| S:13 E:33 ||| JJ
infectious  ||| S:33 E:44 ||| JJ
HIV  ||| S:44 E:48 ||| NN
after  ||| S:48 E:54 ||| IN
genome-directed  ||| S:54 E:70 ||| FW
antiviral  ||| S:70 E:80 ||| FW
endonuclease  ||| S:80 E:93 ||| FW
therapy  ||| S:93 E:101 ||| FW
Incurable  ||| S:101 E:111 ||| FW
chronic  ||| S:111 E:119 ||| FW
viral  ||| S:119 E:125 ||| FW
infections  ||| S:125 E:136 ||| NNS
are  ||| S:136 E:140 ||| VBP
a  ||| S:140 E:142 ||| DT
major  ||| S:142 E:148 ||| JJ
cause  ||| S:148 E:154 ||| NN
of  ||| S:154 E:157 ||| IN
morbidity  ||| S:157 E:167 ||| NN
and  ||| S:167 E:171 ||| CC
mortality  ||| S:171 E:181 ||| NN
worldwide ||| S:181 E:190 ||| NN
.  ||| S:190 E:192 ||| .
One  ||| S:192 E:196 ||| CD
potential  ||| S:196 E:206 ||| JJ
approach  ||| S:206 E:215 ||| NN
to  ||| S:215 E:218 ||| TO
cure  ||| S:218 E:223 ||| VB
persistent  ||| S:223 E:234 ||| JJ
viral  ||| S:234 E:240 ||| JJ
infections  ||| S:240 E:251 ||| NN
is  ||| S:251 E:254 ||| VBZ
via  ||| S:254 E:258 ||| IN
the  ||| S:258 E:262 ||| DT
use  ||| S:262 E:266 ||| NN
of  ||| S:266 E:269 ||| IN
targeted  ||| S:269 E:278 ||| JJ
endonucleases ||| S:278 E:291 ||| NN
.  ||| S:291 E:293 ||| .
Nevertheless ||| S:293 E:305 ||| RB
,  ||| S:305 E:307 ||| ,
a  ||| S:307 E:309 ||| DT
potential  ||| S:309 E:319 ||| JJ
concern  ||| S:319 E:327 ||| NN
for  ||| S:327 E:331 ||| IN
endonuclease-based  ||| S:331 E:350 ||| JJ
antiviral  ||| S:350 E:360 ||| JJ
therapies  ||| S:360 E:370 ||| NN
is  ||| S:370 E:373 ||| VBZ
the  ||| S:373 E:377 ||| DT
emergence  ||| S:377 E:387 ||| NN
of  ||| S:387 E:390 ||| IN
treatment  ||| S:390 E:400 ||| NN
resistance ||| S:400 E:410 ||| NN
.  ||| S:410 E:412 ||| .
Here  ||| S:412 E:417 ||| RB
we  ||| S:417 E:420 ||| PRP
detect  ||| S:420 E:427 ||| VBP
for  ||| S:427 E:431 ||| IN
the  ||| S:431 E:435 ||| DT
first  ||| S:435 E:441 ||| JJ
time  ||| S:441 E:446 ||| NN
an  ||| S:446 E:449 ||| DT
endonuclease-resistant  ||| S:449 E:472 ||| JJ
infectious  ||| S:472 E:483 ||| JJ
virus  ||| S:483 E:489 ||| NN
that  ||| S:489 E:494 ||| WDT
is  ||| S:494 E:497 ||| VBZ
found  ||| S:497 E:503 ||| VBN
with  ||| S:503 E:508 ||| IN
high  ||| S:508 E:513 ||| JJ
frequency  ||| S:513 E:523 ||| NN
after  ||| S:523 E:529 ||| IN
antiviral  ||| S:529 E:539 ||| JJ
endonuclease  ||| S:539 E:552 ||| JJ
therapy ||| S:552 E:559 ||| NN
.  ||| S:559 E:561 ||| .
While  ||| S:561 E:567 ||| IN
testing  ||| S:567 E:575 ||| VBG
the  ||| S:575 E:579 ||| DT
activity  ||| S:579 E:588 ||| NN
of  ||| S:588 E:591 ||| IN
HIV  ||| S:591 E:595 ||| NNP
pol-specific  ||| S:595 E:608 ||| FW
zinc  ||| S:608 E:613 ||| FW
finger  ||| S:613 E:620 ||| FW
nucleases  ||| S:620 E:630 ||| FW
( ||| S:630 E:631 ||| -LRB-
ZFNs ||| S:631 E:635 ||| NNP
)  ||| S:635 E:637 ||| -RRB-
alone  ||| S:637 E:643 ||| RB
or  ||| S:643 E:646 ||| CC
in  ||| S:646 E:649 ||| IN
combination  ||| S:649 E:661 ||| NN
with  ||| S:661 E:666 ||| IN
three  ||| S:666 E:672 ||| CD
prime  ||| S:672 E:678 ||| JJ
repair  ||| S:678 E:685 ||| NN
exonuclease  ||| S:685 E:697 ||| VBD
2  ||| S:697 E:699 ||| CD
( ||| S:699 E:700 ||| -LRB-
Trex2 ||| S:700 E:705 ||| NNP
) ||| S:705 E:706 ||| -RRB-
,  ||| S:706 E:708 ||| ,
we  ||| S:708 E:711 ||| PRP
identified  ||| S:711 E:722 ||| VBD
a  ||| S:722 E:724 ||| DT
treatment-resistant  ||| S:724 E:744 ||| JJ
and  ||| S:744 E:748 ||| CC
infectious  ||| S:748 E:759 ||| JJ
mutant  ||| S:759 E:766 ||| JJ
virus  ||| S:766 E:772 ||| NN
that  ||| S:772 E:777 ||| WDT
was  ||| S:777 E:781 ||| VBD
derived  ||| S:781 E:789 ||| VBN
from  ||| S:789 E:794 ||| IN
a  ||| S:794 E:796 ||| DT
ZFN-mediated  ||| S:796 E:809 ||| JJ
disruption  ||| S:809 E:820 ||| NN
of  ||| S:820 E:823 ||| IN
reverse  ||| S:823 E:831 ||| JJ
transcriptase  ||| S:831 E:845 ||| NNS
( ||| S:845 E:846 ||| -LRB-
RT ||| S:846 E:848 ||| NNP
) ||| S:848 E:849 ||| -RRB-
.  ||| S:849 E:851 ||| .
Although  ||| S:851 E:860 ||| IN
gene  ||| S:860 E:865 ||| NN
disruption  ||| S:865 E:876 ||| NN
of  ||| S:876 E:879 ||| IN
HIV  ||| S:879 E:883 ||| NNP
protease ||| S:883 E:891 ||| NN
,  ||| S:891 E:893 ||| ,
RT  ||| S:893 E:896 ||| NNP
and  ||| S:896 E:900 ||| CC
integrase  ||| S:900 E:910 ||| NNS
could  ||| S:910 E:916 ||| MD
inhibit  ||| S:916 E:924 ||| VB
viral  ||| S:924 E:930 ||| JJ
replication ||| S:930 E:941 ||| NN
,  ||| S:941 E:943 ||| ,
a  ||| S:943 E:945 ||| DT
chance  ||| S:945 E:952 ||| NN
single  ||| S:952 E:959 ||| JJ
amino  ||| S:959 E:965 ||| JJ
acid  ||| S:965 E:970 ||| NN
insertion  ||| S:970 E:980 ||| NN
within  ||| S:980 E:987 ||| IN
the  ||| S:987 E:991 ||| DT
thumb  ||| S:991 E:997 ||| NN
domain  ||| S:997 E:1004 ||| NN
of  ||| S:1004 E:1007 ||| IN
RT  ||| S:1007 E:1010 ||| NNP
produced  ||| S:1010 E:1019 ||| VBD
a  ||| S:1019 E:1021 ||| DT
virus  ||| S:1021 E:1027 ||| NN
that  ||| S:1027 E:1032 ||| WDT
could  ||| S:1032 E:1038 ||| MD
actively  ||| S:1038 E:1047 ||| RB
replicate ||| S:1047 E:1056 ||| VB
.  ||| S:1056 E:1058 ||| .
The  ||| S:1058 E:1062 ||| DT
endonuclease-resistant  ||| S:1062 E:1085 ||| JJ
virus  ||| S:1085 E:1091 ||| NN
could  ||| S:1091 E:1097 ||| MD
replicate  ||| S:1097 E:1107 ||| VB
in  ||| S:1107 E:1110 ||| IN
primary  ||| S:1110 E:1118 ||| JJ
CD4 ||| S:1118 E:1121 ||| NNP
( ||| S:1121 E:1122 ||| -LRB-
+ ||| S:1122 E:1123 ||| NNP
)  ||| S:1123 E:1125 ||| -RRB-
T  ||| S:1125 E:1127 ||| NN
cells ||| S:1127 E:1132 ||| NNS
,  ||| S:1132 E:1134 ||| ,
but  ||| S:1134 E:1138 ||| CC
remained  ||| S:1138 E:1147 ||| VBD
susceptible  ||| S:1147 E:1159 ||| JJ
to  ||| S:1159 E:1162 ||| TO
treatment  ||| S:1162 E:1172 ||| NN
with  ||| S:1172 E:1177 ||| IN
antiretroviral  ||| S:1177 E:1192 ||| FW
RT  ||| S:1192 E:1195 ||| FW
inhibitors ||| S:1195 E:1205 ||| FW
.  ||| S:1205 E:1207 ||| .
When  ||| S:1207 E:1212 ||| WRB
secondary  ||| S:1212 E:1222 ||| JJ
ZFN-derived  ||| S:1222 E:1234 ||| JJ
mutations  ||| S:1234 E:1244 ||| NNS
were  ||| S:1244 E:1249 ||| VBD
introduced  ||| S:1249 E:1260 ||| VBN
into  ||| S:1260 E:1265 ||| IN
the  ||| S:1265 E:1269 ||| DT
mutant  ||| S:1269 E:1276 ||| JJ
virus ||| S:1276 E:1281 ||| NN
's  ||| S:1281 E:1284 ||| POS
RT  ||| S:1284 E:1287 ||| NNP
or  ||| S:1287 E:1290 ||| CC
integrase  ||| S:1290 E:1300 ||| JJ
domains ||| S:1300 E:1307 ||| NN
,  ||| S:1307 E:1309 ||| ,
replication  ||| S:1309 E:1321 ||| NNS
could  ||| S:1321 E:1327 ||| MD
be  ||| S:1327 E:1330 ||| VB
abolished ||| S:1330 E:1339 ||| VBN
.  ||| S:1339 E:1341 ||| .
Our  ||| S:1341 E:1345 ||| PRP$
observations  ||| S:1345 E:1358 ||| NNS
suggest  ||| S:1358 E:1366 ||| VBP
that  ||| S:1366 E:1371 ||| DT
caution  ||| S:1371 E:1379 ||| NN
should  ||| S:1379 E:1386 ||| MD
be  ||| S:1386 E:1389 ||| VB
exercised  ||| S:1389 E:1399 ||| VBN
during  ||| S:1399 E:1406 ||| IN
endonuclease-based  ||| S:1406 E:1425 ||| JJ
antiviral  ||| S:1425 E:1435 ||| JJ
therapies ||| S:1435 E:1444 ||| NNS
;  ||| S:1444 E:1446 ||| :
however ||| S:1446 E:1453 ||| RB
,  ||| S:1453 E:1455 ||| ,
combination  ||| S:1455 E:1467 ||| NN
endonuclease  ||| S:1467 E:1480 ||| NN
therapies  ||| S:1480 E:1490 ||| NNS
may  ||| S:1490 E:1494 ||| MD
prevent  ||| S:1494 E:1502 ||| VB
the  ||| S:1502 E:1506 ||| DT
emergence  ||| S:1506 E:1516 ||| NN
of  ||| S:1516 E:1519 ||| IN
resistance ||| S:1519 E:1529 ||| NN
.  ||| S:1529 E:1531 ||| .
